You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Low Cost Production of Carbon Monofluoride (CFx) for Lithium Batteries

    SBC: REACTIVE INNOVATIONS, LLC            Topic: DLA122002

    Li/CFx primary batteries are considered to be a superior choice for military applications that require long life, light weight and very low self-discharge. The high cost of current carbon monofluoride materials, however, adds significantly to the total cost of the battery. Reactive Innovations, LLC (RIL) proposes to develop a method to produce CFx materials with over a 50% cost saving. The process ...

    SBIR Phase I 2014 Department of DefenseDefense Logistics Agency
  2. An Integrated Li-ion Battery Manufacturing Process for Improved Safety and Decreased Battery Cost

    SBC: GINER INC            Topic: DLA122002

    Commercial separators for Li-ion battery applications consist of microporous membranes that prevent contact between electrodes and enable free ion flow in the cell. Major drawbacks of these separators include their complex manufacturing process which adds cost to the battery and insufficient protection against thermal runaway reactions at elevated temperatures. This project addresses these limitat ...

    SBIR Phase I 2014 Department of DefenseDefense Logistics Agency
  3. Development of a Biomarker Based assay for Hepato cellular Carcinoma-- Rapid test for HCV Core Antigen

    SBC: QOOLABS INC            Topic: N/A

    HCV infects about 3% of the world's population and most people are unaware of the infection status. About 80% of individuals with HCV infection develop chronic hepatitis and many progress to have cirrhosis and hepatocellular carcinoma (HCC). An early diagnosis in the course of the disease not only increases the chances successful treatment, but also effectively limits further transmission of HCV ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  4. Magneto- NanoSensor for Detection of Serum Biomarkers Associated with HepatoCellular Cancer

    SBC: Ocean Nanotech LLC            Topic: N/A

    Liver Cancer is the sixth most common cancer and the third leading cause of cancer death worldwide. Early diagnosis of liver cancer will have a significant impact on survival by implementation of effective tratment strategies. The development of novel biomarkers in serum for liver cancer proteomics will significantly improve noninvasive for early detection of liver cancer. This proposal is to ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  5. Research and identify a confidential and technologically feasible method to communicate HIV/STD and preventive EOB information to young woman through a mobile application

    SBC: Engineered Care, Inc.            Topic: N/A

    The project goal is to research and identify a confidential and technologically feasible method to communicate HIV/STD and preventive EOB information to young woman ages 19 to 25 through a moble application. Engineered Care will speak with privacy and HIPPA experts, payors, technology experts managing payor claims data and youth advocates to prototype a feasible smartphone mobile application. EC i ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  6. Quality-Related eMeasures from EHR Data

    SBC: Commonwealth Informatics, Inc.            Topic: N/A

    To assess the readiness of EHR systems to support this new capability by constructing prototype eMeasure software, interfaced to at least one EHR system, that implements the chlamydia screening rate eMeasure based on HEDIS specifications for the numerator and denominator. Success in Plase I will support a Phase II activity to extend the prototype to additional EHR systems and additional existing a ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  7. Lab research for the development of anti-diphetheria antibodies in humans

    SBC: Planet Biotechnology Incorporated            Topic: N/A

    Diphtheria is an acute bacterial disease with a considerable case fatality rate caused by toxigenic Corynebacteria. Diphtheria toxin (DT) is the major virulence factor for these organisms. DT is synthesized and secreted as a single-polypeptide pro-enzyme that is cleaved and reduced in vivo to produce a toxic protein consisting of A and B fragments (1). DT has an estimated lethal dose for humans of ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  8. Lab research for the development of human anti-diphtheria Mabs in CHO cells

    SBC: ANTAGEN BIOSCIENCES INC            Topic: N/A

    Monoclonal anitbodies (Mab) have been used successfully for treating human diseases. However, conventional Mabs are derived from mouse. Injection of murine Mabs into humans will cause adverse effects. The development of human Mabs against diphtheria could offer a commercially viable alternative to equine antitoxin for treating human diphtheria with a number of potential advantages including hig ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  9. Development of Gap Junction Inhibition Therapy for Alcoholic Liver Disease

    SBC: HEPROTECH, INC.            Topic: NIAAA

    ? DESCRIPTION (provided by applicant): Alcoholic liver disease is a highly prevalent and costly condition affecting millions of people globally. Alcohol results in high morbidity and mortality an is responsible for nearly 4% of all deaths worldwide. Despite the tremendous societal and economic burden, there is no approved therapeutics for alcoholic liver disease. Instead, the standard of care ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Clinically suitable approach for gene-mediated therapy of cirrhosis.

    SBC: ADVANTAGENE, INC            Topic: NIAAA

    Abstract Persistent injury to the liver can cause chronic inflammation and dysregulated deposition of extracellular matrix (ECM), leading to accumulation of fibrotic scar tissue and eventually cirrhosis. While fibrosis is a normal wound healing response, in excess, it can further injure tissue and activate pro-fibrotic cells, resulting in a positive feedback loop. Scar tissue is not static, ECM re ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government